Incorporated in 2014, Pinnacle Life Sciences is the wholly owned subsidiary of Aarti Drugs Limited. It manufactures Active Pharmaceutical Ingredients (APIs) – Oncology/Potent APIs, pharmaceutical formulations, and pharma intermediates. Pinnacle has 13 state-of-the-art cGMP-compliant manufacturing facilities across Maharashtra (Tarapur) and Gujrat (Sarigam).

The formulation R&D centers are located at Turbhe (Maharashtra), Baddi (Chandigarh), and Sikkim. Our R&D centers are equipped with Air Handling Units (AHU), built-in Personnel Safety and Fire Safety Systems, and DG & ETP Systems, ensuring the highest level of security for our 5000+ employees.

Currently, we are marketing products in over 94 countries with a strong presence in regulated markets, including the EU, Brazil, and Mexico. Some of our leading clients include Abbott, Sanofi-Aventis, Merck, Teva, Pfizer, Bayer, Clariant, etc. Furthermore, our partnerships with companies across Europe, the USA, Canada, Brazil, and Chile have allowed us to expand our footprints across the globe.

At Pinnacle, we are proud of our comprehensive portfolio with a strong presence in both acute and chronic ailment medication. Some of the notable formulations that put us on the world map are Rivaroxaban, Apixaban, and Bicalutamide, among others.

We are Rivaroxaban and Apixaban manufacturers. Both these drugs belong to our CNS category. While both drugs are potent anticoagulants, Rivaroxaban is often used to treat deep vein thrombosis (DVT) and pulmonary embolism, and Apixaban is used for treating prophylaxis of stroke and systemic embolism in nonvalvular atrial fibrillation, and deep vein thrombosis.

Bicalutamide belongs to our oncology category. It is an androgen receptor inhibitor. As the Bicalutamide manufacturer at Pinnacle, we make sure it is produced in isolated manufacturing areas in our newly built state-of-the-art oncology medicine manufacturing unit located in Baddi to uphold the utmost quality for fighting stage D2 metastatic prostate cancer.